跳至主要内容
临床试验/NCT07561502
NCT07561502已完成不适用

Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue (Peri III Study)

Francis Medical Inc.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2022年11月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
32
试验地点
1
主要终点
Lesion Characterization by Location and Thermal Damage

研究概览

简要总结

This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate. Researchers will also determine the best treatment dose, monitor safety during and immediately after the procedure, and examine prostate tissue after surgical removal to confirm how well the treatment destroyed targeted tissue. Patients enrolled have been diagnosed with prostate cancer and will undergo treatment with the Vanquish System before their scheduled radical prostatectomy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Subject is 40 years or older
  • Subjects is diagnosed with clinically localized prostate cancer (Stage I (T1c) or Stage II (T2a, T2b, T2c tumor) prostate cancer) AND scheduled for a radical prostatectomy or cystoprostatectomy due to the presence of prostate cancer
  • Subject has a positive biopsy for prostate cancer with Gleason score of 8 (4+4) and below
  • Subject who provides written consent to participate in the study

排除标准

  • Subject with prostate biopsy performed within 42 days from date of prostatectomy.
  • Subject has a known allergy to nickel.
  • Subject who had previous rectal surgery (other than hemorrhoidectomy)
  • Subject with known history of rectal disease.
  • Subject currently participating in other premarket investigational studies.
  • Subject who had a previous TURP or prostatectomy.

研究组 & 干预措施

Treatment with Vanquish System

Experimental

干预措施: Water Vapor Ablation (Device)

结局指标

主要结局

Lesion Characterization by Location and Thermal Damage

时间窗: Evaluated immediately post procedure.

The primary efficacy endpoint is a lesion characterization from the Peri III Study vapor treatment as evaluated by TTC stain. Immediately following treatment and surgical extirpation, the prostate was examined for any external thermal injury followed by whole mount sectioning and staining using tetrazolium chloride (TTC). The whole mount sections were photographed before and after TTC staining. The sections and photographs were examined for ablation within all anatomic regions of the prostate and the ability to ablate to different regions and zones of the prostate.

次要结局

  • Adequacy Scale to Measure Visualization During Procedure(From the beginning to the end of the treatment procedure.)
  • Safety Measurements(Through 30 days following procedure.)

研究者

发起方
Francis Medical Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验